1. Highly cross-linked arabinoxylans microspheres as a microbiota-activated carrier for colon-specific insulin delivery
- Author
-
Yolanda L. López-Franco, A.M. Morales-Burgos, Elizabeth Carvajal-Millan, Jaime Lizardi-Mendoza, Norberto Sotelo-Cruz, R. Canett-Romero, Marcel Martínez-Porchas, and Agustín Rascón-Chu
- Subjects
Male ,Colon ,medicine.medical_treatment ,Pharmaceutical Science ,Administration, Oral ,02 engineering and technology ,Pharmacology ,030226 pharmacology & pharmacy ,Streptozocin ,Microsphere ,Diabetes Mellitus, Experimental ,03 medical and health sciences ,0302 clinical medicine ,Polyuria ,In vivo ,Diabetes mellitus ,medicine ,Animals ,Humans ,Insulin ,Intestinal Mucosa ,Bifidobacterium ,Drug Carriers ,biology ,Chemistry ,General Medicine ,021001 nanoscience & nanotechnology ,biology.organism_classification ,medicine.disease ,Microspheres ,Gastrointestinal Microbiome ,Rats ,Diabetes Mellitus, Type 1 ,Diabetes Mellitus, Type 2 ,Drug delivery ,Xylans ,Bacteroides ,medicine.symptom ,0210 nano-technology ,Biotechnology - Abstract
In vivo evaluation of arabinoxylans (AX) microspheres showed to protect insulin from degradation in the upper gastrointestinal tract and carrier insulin to colon. Insulin-loaded AX microspheres (50 UI/kg) decreased blood glucose level by 39% in diabetic rats with a maximum effect at 18 h post-administration, indicating that insulin remains bioactive. The continuous administration (4 days) of insulin-loaded AX microspheres improved the polyuria and increased the production of short-chain fatty acids, as well as Bifidobacterium and Bacteroides in diabetic rats compared to untreated diabetic rats. AX microspheres are a potential microbiota-activated carrier for colon-specific drug delivery and could be useful as a complementary treatment for diabetes.
- Published
- 2020